Arcoma AB develops, produces, and provides radiology solutions worldwide. More Details
Flawless balance sheet with solid track record.
Share Price & News
How has Arcoma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARCOMA has not had significant price volatility in the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: ARCOMA underperformed the Swedish Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: ARCOMA underperformed the Swedish Market which returned 16.4% over the past year.
Price Volatility Vs. Market
How volatile is Arcoma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCalculating The Fair Value Of Arcoma AB (STO:ARCOMA)
1 month ago | Simply Wall StArcoma (STO:ARCOMA) Seems To Use Debt Quite Sensibly
3 months ago | Simply Wall StThe Arcoma (STO:ARCOMA) Share Price Is Up 207% And Shareholders Are Boasting About It
Is Arcoma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARCOMA (SEK19.75) is trading below our estimate of fair value (SEK26.16)
Significantly Below Fair Value: ARCOMA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ARCOMA is good value based on its PE Ratio (25.8x) compared to the SE Medical Equipment industry average (34.6x).
PE vs Market: ARCOMA is poor value based on its PE Ratio (25.8x) compared to the Swedish market (22.1x).
Price to Earnings Growth Ratio
PEG Ratio: ARCOMA is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: ARCOMA's PB Ratio (4.8x) is in line with the SE Medical Equipment industry average.
How is Arcoma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARCOMA's forecast earnings growth (32.4% per year) is above the savings rate (0.5%).
Earnings vs Market: ARCOMA's earnings (32.4% per year) are forecast to grow faster than the Swedish market (15.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ARCOMA's revenue (19.9% per year) is forecast to grow faster than the Swedish market (3.8% per year).
High Growth Revenue: ARCOMA's revenue (19.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARCOMA's Return on Equity is forecast to be high in 3 years time (20.1%)
How has Arcoma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARCOMA has high quality earnings.
Growing Profit Margin: ARCOMA's current net profit margins (7.5%) are higher than last year (1.9%).
Past Earnings Growth Analysis
Earnings Trend: ARCOMA has become profitable over the past 5 years, growing earnings by 53.8% per year.
Accelerating Growth: ARCOMA's earnings growth over the past year (287.3%) exceeds its 5-year average (53.8% per year).
Earnings vs Industry: ARCOMA earnings growth over the past year (287.3%) exceeded the Medical Equipment industry 17.2%.
Return on Equity
High ROE: ARCOMA's Return on Equity (18.6%) is considered low.
How is Arcoma's financial position?
Financial Position Analysis
Short Term Liabilities: ARCOMA's short term assets (SEK49.0M) exceed its short term liabilities (SEK30.3M).
Long Term Liabilities: ARCOMA's short term assets (SEK49.0M) exceed its long term liabilities (SEK2.9M).
Debt to Equity History and Analysis
Debt Level: ARCOMA's debt to equity ratio (20.3%) is considered satisfactory.
Reducing Debt: ARCOMA's debt to equity ratio has reduced from 33.7% to 20.3% over the past 5 years.
Debt Coverage: ARCOMA's debt is well covered by operating cash flow (186.7%).
Interest Coverage: ARCOMA's interest payments on its debt are well covered by EBIT (22.6x coverage).
What is Arcoma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARCOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARCOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARCOMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARCOMA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARCOMA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Arcoma has no CEO, or we have no data on them.
|Director||0.25yr||no data||0.20% |
Experienced Board: ARCOMA's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Arcoma AB's company bio, employee growth, exchange listings and data sources
- Name: Arcoma AB
- Ticker: ARCOMA
- Exchange: OM
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr252.405m
- Shares outstanding: 12.78m
- Website: https://www.arcoma.se
Number of Employees
- Arcoma AB
- Annavägen 1
- Kronoberg County
- 352 46
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ARCOMA||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Nov 2014|
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skelet ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/18 02:54|
|End of Day Share Price||2020/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.